Sign In
Buy PCRX
$22.32
+0.0700 (+0.315%)
At Close: Jun 03, 2026
Pacira BioSciences Completes Acquisition of Flexion Therapeutics and Strengthens Leadership Position in Non-Opioid Pain Management
01:40pm, Friday, 19'th Nov 2021 GlobeNewswire Inc.
-- Adds highly complementary ZILRETTA® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opioid solutions along the pain pathway --
Pacira's (PCRX) Q3 Earnings Beat Estimates, Revenues Miss Mark
02:33pm, Wednesday, 03'rd Nov 2021
Pacira's (PCRX) earnings beat estimates in the third quarter of 2021 while revenues miss the same. Its flagship product Exparel's sales rise year over year.
Pacira BioSciences, Inc. (PCRX) CEO Dave Stack on Q3 2021 Results - Earnings Call Transcript
01:48pm, Wednesday, 03'rd Nov 2021
Pacira BioSciences, Inc. (PCRX) CEO Dave Stack on Q3 2021 Results - Earnings Call Transcript
Pacira (PCRX) Beats Q3 Earnings Estimates
10:43am, Wednesday, 03'rd Nov 2021
Pacira (PCRX) delivered earnings and revenue surprises of 9.09% and -2.11%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Pacira to Report Third Quarter 2021 Financial Results on Wednesday November 3, 2021
07:30am, Wednesday, 27'th Oct 2021
PARSIPPANY, N.J., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results before the open of the U.S. markets o
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Flexion Therapeutics, Inc.
04:26pm, Monday, 11'th Oct 2021
NEW YORK, Oct. 11, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Flexion Therapeutics, Inc. (NASDAQ: FLXN) and its board of directors concerning the pro
FLXN Stock Is Winning Big Today Ahead of Merger With Pacira
01:38pm, Monday, 11'th Oct 2021
FLXN stock is surging upward today as the company announces a merger with fellow biopharma play Pacira, valuing the company at $450 million. The post FLXN Stock Is Winning Big Today Ahead of Merger Wi
Pacira Beefs Up Non-Opioid Pain Management Via Flexion Acquisition
08:57am, Monday, 11'th Oct 2021
Pacira BioSciences Inc (NASDAQ: PCRX) has agreed to acquire Flexion Therapeutics Inc (NASDAQ: FLXN) for $8.50 per share in cash, plus one contingent value right (CVR) worth up to $8.00 per share i
Flexion Therapeutics shares soar 39% premarket on news to be acquired by Pacira Biosciences
07:13am, Monday, 11'th Oct 2021
Tampa, Fla.-based Pacira BioSciences Inc. PCRX, -1.34% said Monday it is acquiring Flexion Therapeutics Inc. FLXN, +2.30% , based in Burlington, Mass.
Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management
07:00am, Monday, 11'th Oct 2021
-- Adds highly complementary ZILRETTA® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opioid solutions along the pain pathway --
Pacira BioSciences to Host Investor Day on October 15th, 2021 in Tampa, FL
08:00am, Friday, 08'th Oct 2021
TAMPA, Fla., Oct. 08, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today anno
Why Pacira Biosciences Stock Sank Today
03:56pm, Monday, 04'th Oct 2021
A potential rival hopes to win FDA approval of a generic version of Pacira's top-selling pain drug.
Pacira BioSciences Notified of Abbreviated New Drug Application Filing for EXPAREL®
07:30am, Monday, 04'th Oct 2021
TAMPA, Fla., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, has recei
Pacira Announces Commercial Production Underway with Enhanced EXPAREL Manufacturing Process at Swindon Facility
07:30am, Thursday, 30'th Sep 2021
Marks key step in achieving EXPAREL gross margins that exceed 85 percent by 2024 Marks key step in achieving EXPAREL gross margins that exceed 85 percent by 2024
ImmuneID Appoints Veteran Biotech Executive James S. Scibetta as CEO
08:00am, Tuesday, 21'st Sep 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--ImmuneID appoints veteran biotech executive James S. Scibetta as Chief Executive Officer.
